The effect of cyclosporine administration on the cellular distribution and content of cyclophilin.
Cyclophilin (CYP), an intracellular protein sharing amino acid sequence identity with the enzyme peptidyl-prolyl cis-trans isomerase has become the leading candidate for the receptor responsible for cyclosporine biological effects. Avid binding of CYP to cyclosporine and immunosuppressive cyclosporine metabolites has been demonstrated, while nonimmunosuppressive cyclosporine metabolites have tended not to bind to cyclophilin. A previous immunohistochemical analysis documented that CYP localized principally to the cytoplasmic cellular compartment, but nuclear staining was observed among some cells. This study was undertaken to more precisely define the ultrastructural distribution of CYP, and to determine whether CYP cellular content was affected by CsA therapy. Untreated Wistar rats or those receiving 7 days of CsA (15 mg/kg/day, i.p.) were anesthetized, perfusion-fixed in situ, and sacrificed. Analyses of lymph node, spleen, thymus, kidney, liver, heart, brain, and ileum used an affinity purified, rabbit anticyclophilin IgG. Transmission electron microscopy was performed after staining with anti-CYP using a horseradish peroxidase/biotin/avidin technique. Quantitative immunofluorescence was measured by confocal microscopy using anti-CYP, with a biotin/avidin/phycoerythrin technique. Cyclophilin localized to the cytoplasmic compartment--however, association with mitochondria endoplasmic reticulum, Golgi, and with the nuclear membrane among lymphocytes, as well as cells from kidney, liver and ileum--was documented. Cyclophilin was not identified within the nucleus proper. Tissues obtained from animals receiving CsA exhibited a generalized increase in CYP content compared with tissues from untreated controls, suggesting the possibility that CsA may exert a regulatory influence upon CYP gene activation. Collectively, the data were consistent with the hypothesis that CYP exerts a central role in cellular metabolism, and that CsA-mediated biologic effects result from the CsA/CYP interaction.
McDonald
M L
ML
Department of Surgery, Yale University School of Medicine, New Haven, Connecticut 06510.
Ardito
T
T
Marks
W H
WH
Kashgarian
M
M
Lorber
M I
MI
D000591:Amino Acid Isomerases / Q000097:blood*; D000818:Animals; D002352:Carrier Proteins / Q000097:blood*; D016572:Cyclosporine / Q000008:administration & dosage*; D005260:Female; D007150:Immunohistochemistry; D008099:Liver / Q000737:chemistry / Q000166:cytology; D008214:Lymphocytes / Q000737:chemistry*; D008856:Microscopy, Fluorescence; D016253:Microscopy, Immunoelectron; D019696:Peptidylprolyl Isomerase; D051381:Rats; D011919:Rats, Inbred Strains; D014018:Tissue Distribution
D002352:Carrier Proteins; D016572:Cyclosporine; D000591:Amino Acid Isomerases; D019696:Peptidylprolyl Isomerase